In a research report issue today, Canaccord analyst Mark Massaro maintained a Buy rating on EXACT Sciences Corporation (NASDAQ:EXAS) with a $30 price target, after the company announced a …
Canaccord Genuity analyst Mark Massaro weighed in today with a research note on Quest Diagnostics Inc (NYSE:DGX), following speculation that the company may be exploring a …
Exact Sciences Corporation (NASDAQ:EXAS) surged 11% today after the company reported first-quarter results with revenues beating consensus expectations. In reaction, Canaccord’s healthcare analyst Mark Massaro reiterated a Buy rating on the …
In a research report published Friday, Canaccord Genuity analyst Mark Massaro reiterated a Buy rating on EXACT Sciences Corporation (NASDAQ:EXAS) and raised the price target …
In a research report issued this morning, Canaccord Genuity analyst Mark Massaro maintained a Buy rating on EXACT Sciences Corporation (NASDAQ:EXAS) with a $27 price …
In a research report released today, Canaccord Genuity analyst Mark Massaro reiterated a Buy rating on Exact Sciences Corporation (NASDAQ:EXAS), and reduced the price target to …
Canaccord Genuity’s healthcare analyst Mark Massaro weighed in today with a few insights on EXACT Sciences Corporation (NASDAQ:EXAS), after the stock plunged following the company’s fourth-quarter call. The …
In a research report sent to investors, Canaccord Genuity analyst Mark Massaro downgraded shares of Venaxis (NASDAQ:APPY) from Buy to Hold, and reduced the …
Canaccord Genuity analyst Mark Massaro maintained a Buy rating on Venaxis Inc (NASDAQ:APPY) with a $5.00 price target, which represents a potential upside …
In a research report issued today, Canaccord Genuity analyst Mark Massaro assigned a Buy rating on Cepheid (NASDAQ:CPHD) with a price target of …
